Skip to main content

Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets.

Publication ,  Journal Article
Miao, Y; Medeiros, LJ; Xu-Monette, ZY; Li, J; Young, KH
Published in: Frontiers in oncology
January 2019

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma worldwide, representing 30-40% of non-Hodgkin lymphomas, and is clinically aggressive. Although more than half of patients with DLBCL are cured by using standard first-line immunochemotherapy, the remaining patients are refractory to the first-line therapy or relapse after complete remission and these patients require novel therapeutic approaches. Understanding the pathogenesis of DLBCL is essential for identifying therapeutic targets to tackle this disease. Cell survival dysregulation, a hallmark of cancer, is a characteristic feature of DLBCL. Intrinsic signaling aberrations, tumor microenvironment dysfunction, and viral factors can all contribute to the cell survival dysregulation in DLBCL. In recent years, several novel drugs that target abnormal cell survival pathways, have been developed and tested in clinical trials of patients with DLBCL. In this review, we discuss cell survival dysregulation, the underlying mechanisms, and how to target abnormal cell survival therapeutically in DLBCL patients.

Duke Scholars

Published In

Frontiers in oncology

DOI

EISSN

2234-943X

ISSN

2234-943X

Publication Date

January 2019

Volume

9

Start / End Page

107

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Miao, Y., Medeiros, L. J., Xu-Monette, Z. Y., Li, J., & Young, K. H. (2019). Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets. Frontiers in Oncology, 9, 107. https://doi.org/10.3389/fonc.2019.00107

Published In

Frontiers in oncology

DOI

EISSN

2234-943X

ISSN

2234-943X

Publication Date

January 2019

Volume

9

Start / End Page

107

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis